...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: A couple Q2 events for Zenith

San Fran,

Trump seems to be the antithesis of Coolidge.....after recent political events we may be feeling quite nostalgic for a Coolidge like demeanor. Speaking of Zenith, you wrote "It's nice to see some movement (any movement) at Zenith." I am starting to think that a side effect of ZEN-3694 must be constipation. The information flow from Zenith seems to be extremely backed up. LOL. Coincidentally, the website was updated today only after I had emailed Zenith earlier today asking if they were presenting at BIO Internation or BioEquity Europe (affirmative on the former, negative on the latter). Similar thing happened with AACR conference....the event and poster only appeared on the Zenith website the same day I emailed them, which in that case was the day of the conference.

Zenith will be 11 months into the start of dosing in the single agent ZEN-3694 trial next week, and over 12 months come BIO-International. The ZEN-3694/enzalutamide combo trial will have been dosing for 6 months next week and 7 months come BIO-International. I really hope they turn the BIO-International presentation into a webcast if possible. I think we would all agree that some Miralax is in order to get this information flow moving again.

BearDownAZ

Share
New Message
Please login to post a reply